Is a non-alcoholic fatty liver an inflammatory component of the metabolic syndrome?

Authors

  • Johan Almarza Endocrine-Metabolic Research Center Dr. Félix Gómez

DOI:

https://doi.org/10.17533/udea.penh.9571

Keywords:

fatty liver, metabolic syndrome, oxidative stress

Abstract

Objective: Integrate components that correlate insulin-resistance in the development of non-alcoholic fatty liver and the molecular mechanisms involved in the pathophysiology, diagnostic methods and clinical implications. Methods and materials: A systematic search was conducted of articles from 1990 to 2010, comprised primarily of a period from October 2009 to December 2010, using international data bases like PubMed, ScienceDirect and Ovid. The research for information related to Latin America, including Colombia and Venezuela, was done in Lilacs and Scielo. Medical Subject Headings (Mesh) and each one of the said services were used in determining choice of terms. Results and conclusions: Inflammatory mediators (adipokines), oxidative (reactive oxygen species) and metabolic (free fatty acids) responsible for the natural history of the SM are relative to the development of the non-alcoholic fatty liver (HGNA); therefore the identification of this pathological component through the biochemical methods and relevant ultrasound, is of the utmost importance. Gradual weight loss, increased physical activity, dietary modifications increase the expression of enzymes peroxisomes of the beta oxidation of fatty acids, and prevent their subsequent cytoplasmic accumulation.
|Abstract
= 259 veces | PDF (ESPAÑOL (ESPAÑA))
= 200 veces|

Downloads

Download data is not yet available.

Author Biography

Johan Almarza, Endocrine-Metabolic Research Center Dr. Félix Gómez

Endocrine-Metabolic Research Center Dr. Félix Gómez. Maracaibo-Venezuela.

References

Cornier M, Dabelea D, Hernández T, Lindstrom R, Steig A, Stob N, et al. The metabolic syndrome. Endocrinol Rev. 2008;29: 777-822.

Bagry H. Metabolic syndrome and insulin resistance. Anesthesiology. 2008;108:506-23.

Eckel R. The metabolic SM. Lancet. 2005;365:1415-28.

Roden. Mechanisms of disease:hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab. 2006;2:335-48.

Mendez-Sánchez N, Chavez N, Uribe M. Hígado graso no alcohólico: nuevos conceptos. Investigación Clínica. 2004;56:72-82.

Ludwig J, McGill DB, Lindor KD. Review: nonalcoholic steatohepatitis. J Gastro Hepatol. 1997;12:398-03.

Castera L. Non-invasive diagnosis of steatosis and fibrosis. Diabetes Metab. 2008;34:674-79.

Mehta S, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol. 2009;50:36-41.

Poynard T, Muntenau M, Morra R, Ngo Y, Imbert-Bismut F, Thabut D. Methodological aspects for the interpretation of liver fibrosis non-invasive biomarkers: a 2008 update. Gastroenterol Clin Biol. 2008;32:8-21.

Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol. 2009;50:1-3.

Lemoine S. Definition and natural history of metabolic steatosis clinical aspects of NAFLD, NASH and cirrosis. Diabetes Metab. 2008;34:634-7.

Brent A. Neuschwander-Tetri. Fatty liver and the metabolic SM. Curr Opin Gastroenterol. 2007;23:193-8.

Tordjmana J, Clémenta M, Guerre-Milloa K. Adipose tissue inflammation and liver pathology in human obesity. Diabetes Metab. 2008;34 658-63.

Lafontan M, Girard J. Impact of visceral adipose tissue on liver metabolism. Part I: Heterogeneity of adipose tissue and functional properties of visceral adipose tissue. Diabetes Metab. 2008;34:317-27.

Girard J, Lafontan M. Impact of visceral adipose tissue on liver metabolism and insulin resistance. Part II: Visceral adipose tissue production and liver metabolism. Diabetes Metab. 2008;34:439-45.

Mutch DM, Clément K. Genetics of human obesity. Best Pract Res Clin Endocrinol Metab. 2006;20:647-64.

Tillotson J. America’s obesity: conflicting public policies, industrial economic development, and unintended human consequences. Annu Rev Nutr. 2004;24:617-43.

Mantena S. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol and obesity-induced fatty liver diseases. Free Radic Biol Med. 2008;44:1259-72.

Perlemuter G, Bigorgne A, Cassard-Doulcier A, Naveau S. Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nat Clin Pract Endocrinol Metab. 2007;3:458-69.

Caldwell SH, Chang CY, Nakamoto RK, Krugner-Higby L. Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:595-617.

Postica C, Girarda J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab. 2008;34:643-8.

Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res. 2005;36:232-40.

Voshol PJ, Haemmerle G, Ouwens DM, Zimmermann R, Zechner R, Teusink B, et al. Increased hepatic insulin sensitivity together with decreased hepatic triglyceride stores in hormone-sensitive lipase-deficient mice. Endocrinology. 2003;144:3456-62.

Park SY, Kim HJ, Wang S, Higashimori T, Dong J, Kim YJ. Hormone-sensitive lipase knockout mice have increased hepatic insulin sensitivity and are protected from short-term diet-induced insulin resistance in skeletal muscle and heart. Am J Physiol Endocrinol Metab. 2005;289:30-9.

Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006;91: 4753-61.

Videla A, Rodrigo R, Araya J, Poniachik J. Insulin resistance and oxidative stress interdependency in non alcoholic fatty liver disease. Trends Mol Med. 2006;12:555-8.

Cave M, Deaciuc I, Mendez C, Song Z, Joshi-Barve S, Barve S, et al. Nonalcoholic fatty liver disease:predisposing factors and the role of nutrition. J Nutr Biochem. 2007;18:184-95.

Zulet A. Biomarcadores del estado inflamatorio, nexo de unión con la obesidad y complicaciones asociadas. Nutri Hosp. 2007;22:511-27.

Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-31.

O’shea J, Gadina M, Schreiber R. Cytokine signaling in 2002: New surprises in the Jak/Stat pathway. Cell. 2002;109:S121-S31.

O’shea J, Murray P. Cytokine signaling modules in inflammatory responses. Immunity. 2008;28:477-87.

Wullaert A, Van Loo G, Heyninck K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor kappa beta: effects on liver homeostasis and beyond. Endocrinol Rev. 2007;28:365-86.

Strasser H, McDunn A, Swanson J. Cell death. N Engl J Med. 2009;361:1570-83.

Aggarwal B. Signalling pathways of the TNF super family: a double-edged sword. Nat Rev Immunol. 2003;3:745-56.

Peraldi P, Hotamisligil. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55TNF receptor and activation of sphingomyelinase. J Biol Chem. 1996;271:13018-22.

Liu LM, Spelleken K, Rohring H, Hauner. Tumor necrosis factor-alpha acutely inhibits insulin signaling in human adipocytes:implication of the p80 tumor necrosis factor receptor. Diabetes. 1998;47:515-22.

Uysal K. Functional analysis of tumor necrosis factor (TNF) receptors in TNFalpha- mediated insulin resistance in genetic obesity. Endocrinology. 1998;139:4832-8.

Sethi J, Uysal S Wiesbrock L. Characterization of receptor-specific TNF-alpha functions in adipocyte cell lines lacking type 1 and 2 TNF receptors. FEBS Lett. 2000;469:77-82.

Hotamisligil GS, Arner P, Atkinson RL. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes. 1997;46:451-5.

Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH:TNF-alpha or adiponectin? Hepatology. 2004;40:46-54.

Marra F, Aleffi S, Bertolani C, Petrai I, Vizzutti F. Adipokines and liver fibrosis. Eur Rev Med Pharmacol Sci. 2005;9:279-84.

Musso G, Gambino R, Biroli G, Carello M, Faga E, Pacini G. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2005;100:2438-46.

Trappoliere F, Loguercio C. Treatment of patients with non-alcoholic fatty liver disease: Current views and perspectives. Digest Liver Dis. 2006;38:789-80.

Lingvay I, Raskin P, Szczepaniak L. Effect of insulin–metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications. 2007;21:137-42.

Capeau J. Insulin resistance and steatosis in humans. Diabetes Metab. 2008;34:649-57.

Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone- treated type 2 diabetic patients. J Clin Endocrinol Metab. 2004;89:200-306.

Tiikkainen M, Hakkinen A, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004;53:2169-76.

Machado M, Cortez-Pinto H. Non-alcoholic fatty liver disease and insulin resistance. Eur J Gatroenterol Hepatol. 2005;17:823-6.

Ten S, Maclaren N. Insulin resistance syndrome in children. J Clin Endocrinol Metabol. 2004;89:2596-639.

Festi DA, Sacco T, Bondi M. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obesity Rev. 2004;5:27-42.

Angulo P, Lindor K. Treatment of non-alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol. 2002;16:797-810.

Hughes T. Emerging therapies for metabolic diseases: the focus is on diabetes and obesity. Curr Opin Chem Biol. 2009;13:1-6.

Downloads

Published

2011-07-10

How to Cite

Almarza, J. (2011). Is a non-alcoholic fatty liver an inflammatory component of the metabolic syndrome?. Perspectivas En Nutrición Humana, 12(2), 163–175. https://doi.org/10.17533/udea.penh.9571

Issue

Vol. 12 No. 2 (2010)

Section

Review articles

License

Derechos de autor 2024 Universidad de Antioquia

Crossref
Scopus
Google Scholar
Europe PMC